The Drugs Controller General of India (DCGI) is considering banning over-the-counter (OTC) sales of pain relievers Tapentadol and Pregabalin to curb misuse. Pregabalin is prescribed for neuropathic pain and fibromyalgia, while Tapentadol is used for seizures. The DCGI has constituted a sub-committee to review the matter, including experts from the regulator's office, clinicians, and pharmacologists.